panel discussion on os data from keynote-564 study and post-relapse treatment selection
Published 8 months ago • 921 plays • Length 10:51Download video MP4
Download video MP3
Similar videos
-
9:29
keynote-564 study
-
12:23
asco® gu data updates: keynote-564 and checkmate 914
-
1:50
keynote 564 update
-
1:00
adjuvant pembrolizumab in kidney cancer from keynote 564
-
5:33
keynote-564: pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with...
-
1:00
long term survival data from the phase iii keynote-054 trial
-
4:46
panel comments on most impactful studies and data in bladder cancer
-
1:17
dr. zhang discusses the keynote-564 trial in rcc
-
1:06:46
dr bakshi | panel discussion
-
3:02
updates from keynote 57: pembrolizumab for patients with bladder cancer
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
1:13:12
genitourinary cancer webinar held on april 23, 2024
-
2:22
adjuvant pembrolizumab and survival in renal-cell carcinoma | nejm
-
1:08:16
the uromigos: perioperative therapy in rcc
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
1:28:18
navigating evolving standards of care in rcc: novel targeted and immunotherapy options
-
18:55
2021 west oncology app | new renal cell treatment options update
-
24:23
2019 advances in cancer immunotherapy panel discussion